Adaptive Biotechnologies Corporation

(ADPT) Trade

By |

Profile

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Contact Information

Website: www.adaptivebiotech.com
Main Phone: +1 206 659-0067
Address: 1551 Eastlake Avenue East
Address 2: Suite 200
State: WA
City / Town: Seattle
Country: US
Postal Code: 98102

Issuer Information

Exchange: NGS
CEO: Chad Robins
Employees: 453
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Contact Information

Website: www.adaptivebiotech.com
Main Phone: +1 206 659-0067
Address: 1551 Eastlake Avenue East
Address 2: Suite 200
State: WA
City / Town: Seattle
Country: US
Postal Code: 98102

Issuer Information

Exchange: NGS
CEO: Chad Robins
Employees: 453
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 49.43 $ 0.80 (1.65%)
Last Price 49.43 Change $ 0.80 Change % 1.65 Tick N/A
Bid 47.00 Bid Size 100.00 Ask 50.44 Ask Size 300.00
Open 49.00 High 50.16 Low 48.08 Prev Close 48.63
Last Trade Volume 1.4 mi 52 Wk Hi 50.70 52 Wk Low 15.19
Market Cap 6.7 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 135,793,728.00 EPS (TTM) -0.66 PE Ratio N/A Exchange NGS